Follow on Google News News By Tag * Hepatitis B Market * Forecast * Insight * Baraclude * Viread * Research * Market Research Reports * Market Research * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | Forecast Insight: Hepatitis B - Baraclude and Viread now available at ReportsandReportsIn 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009.
By: ReportsandReports Browse complete Report on: http://www.reportsandreports.com/ Introduction In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between 2005 and 2009. Datamonitor expects the market to grow to $1.2 billion by 2014. However, from 2015 to 2019, sales across the seven major markets will decline due to patent expiries of key drugs such as Baraclude and Viread, and reach approximately $893m by 2019. Scope * Analysis of the current hepatitis B market dynamics across the US, 5EU, Japan and Turkey, with a snapshot of the Rest of World countries * Thorough assessment of key marketed products for hepatitis B therapy * Detailed ten-year sales forecasts for marketed hepatitis B drugs in each of the seven major markets and Turkey * Review of opinions of key hepatitis B opinion leaders on future market developments Highlights In 2009, small molecule antivirals dominated the hepatitis B market with sales of $954m. In comparison, sales of interferon products were low, accounting for only 3% of total hepatitis B sales in 2009. This low market share can be attributed to the high cost of interferon products, their restricted use and inconvenient mode of administration. Market growth until 2014 will be driven by the strong uptake of newer hepatitis B antivirals such as Bristol-Myers Squibb's Baraclude (entecavir) and Gilead's Viread (tenofovir). Older products such as Gilead's Hepsera (adefovir) and GlaxoSmithKline's Zeffix (lamivudine) In 2009, Baraclude was the best selling brand in terms of value in Turkey; however Zeffix dominated in terms of volume. The popularity of Zeffix can be explained by the stringent reimbursement policy in Turkey, which restricts the use of more expensive drugs such as the pegylated interferons, Baraclude and Viread to specific populations. Reasons to Purchase * Understand the changing market dynamics of hepatitis B drugs and success factors for leading brands. * Assess the impact of events such as patent expiries on the overall hepatitis B market. * Obtain full, country, class and product-specific forecasts of currently marketed drugs from 2009 to 2019 for all seven major markets and Turkey. Table Of Contents Overview Catalyst Summary About Datamonitor healthcare About the Infectious Diseases pharmaceutical analysis team Executive Summary Strategic scoping and focus Datamonitor insight into the Hepatitis B market Related reports Upcoming related reports Table of Contents Table of figures Table of tables Market definition and overview Market definition for this report Countries and regions included in this report Seven major market assessment Current and future market overview Small molecule antivirals will continue to dominate sales Pegylated interferon sales to remain steady over the forecast period Genericization will lead to an overall decline in sales across the seven major markets Impact of vaccination will reduce hepatitis B incidence but immigration will keep prevalence rates stable across the seven major markets US healthcare reform will increase the number of patients accessing therapy EU countries are increasingly looking to cut healthcare spending Japan implements biennial price cuts to contain costs Comparison with previous forecast Viread achieves higher peak sales, reflecting the drug's fast uptake Combination therapy is unlikely to be used in first-line therapy in the near future Tyzeka/ Clevudine has been excluded from the 2010 forecasts Pegasys uptake has been slower than anticipated owing to the success of Baraclude and Viread Rest of the world snapshot Brand Dynamics Overview of the competitive landscape Small molecule antivirals Viread HBV (tenofovir disoproxil fumarate; Gilead Sciences) High efficacy and genetic barrier to resistance wins recommendation for first-line therapy Viread is anticipated to be market leader by 2016, but generic incursion will slow growth thereafter Baraclude (entecavir, Bristol-Myers Squibb) Lack of differentiation between Baraclude and Viread will intensify competition in the first-line Zeffix resistance restricts Baraclude's role in second-line therapy Baraclude's patent expiry in 2015-16 will negatively impact Baraclude and Viread sales Hepsera (adefovir dipivoxil; Gilead Sciences) Hepsera use is set to decline following the introduction of Viread Pegylated interferons Pegasys (peginterferon alpha-2a, Roche) Limited role in hepatitis B therapy will prevent further growth Biosimilar uptake will remain low following Pegasys's patent expiry in 2017 Turkey Market overview General characteristics Demographics Economics Healthcare spending and access Reimbursement Intellectual property environment Drug approval process Drug pricing Treatment guidelines Hepatitis B epidemiology Current and future overview of the hepatitis B market in Turkey Initial market growth will be followed by sales decline as genericization increases Baraclude and Viread will emerge as clear market leaders as resistance against Zeffix increases Bibliography Journal papers Websites Datamonitor reports Browse complete Report on: http://www.reportsandreports.com/ Browse all Healthcare Market Research Reports on: http://www.reportsandreports.com/ Browse all Datamonitor Market Research Reports on: http://www.reportsandreports.com/ Browse all Latest Report on: http://www.reportsandreports.com/ Related Reports: Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents http://www.reportsandreports.com/ Hepatitis B Market Forecast http://www.reportsandreports.com/ Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition http://www.reportsandreports.com/ About Us: Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers. Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004 Website: http://www.reportsandreports.com/ Blog: http://reportsnreports.wordpress.com/ Blog: http://reportsandreports.blogspot.com/ # # # Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
